Posted On: 08/13/2014 10:31:25 AM
Post# of 102468
$GILD Recent Headlines
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt
Gilead Sovaldi sales reach $3.48B, ahead of $2.87B view 4:10 p.m. July 23, 2014 - Russ Britt
Gilead's $6.53B in revs. beats $5.85B estimate 4:10 p.m. July 23, 2014 - Russ Britt
Gilead adj. earns are $2.36/share vs. view of $1.79 4:09 p.m. July 23, 2014 - Russ Britt
Gilead revs. $6.5 billion vs. year-ago $2.77 billion 4:08 p.m. July 23, 2014 - Russ Britt
Gilead Q2 net is $2.20 vs. year-ago 46 cents 4:07 p.m. July 23, 2014 - Russ Britt
4 ways Gilead’s earnings will impact every American 1:30 p.m. July 23, 2014 - Tim Mullaney
Gilead's moment of truth arrives: How does Sovaldi impact earnings? 1:18 p.m. July 23, 2014 - blogs.marketwatch.com
Gilead (GILD) Hits New Lifetime High Today 42 min ago - TheStreet.com
Celladon (CLDN) Falls: Stock Goes Down 6.2% - Tale of the Tape 8:30 a.m. Today - Zacks.com
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day 3:06 a.m. Today - Zacks.com
Apple, Facebook Among 5 Top Rated Big Cap Stocks 7:18 p.m. Aug. 12, 2014 - Investors Business Daily
Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog 5:20 p.m. Aug. 12, 2014 - Zacks.com
Tekmira Shares Continue to Rise in the Search for Ebola Cure - Analyst Blog 4:20 p.m. Aug. 12, 2014 - Zacks.com
Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog 2:49 p.m. Aug. 12, 2014 - Zacks.com
Gilead Sciences Looks Like A Contrarian Short 12:51 p.m. Aug. 12, 2014 - Seeking Alpha
Arrowhead's Hep B Phase 2a Topline Data Imminent - 'Transformational' Potential 12:27 p.m. Aug. 12, 2014 - Seeking Alpha
Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 - Analyst Blog 11:30 a.m. Aug. 12, 2014 - Zacks.com
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog 11:05 a.m. Aug. 12, 2014 - Zacks.com
Supernus (SUPN) Posts Strong Earnings in Q2, Guidance Raised - Analyst Blog 10:38 a.m. Aug. 12, 2014 - Zacks.com
Anacor's Q2 Loss Narrower than Expected, Kerydin in Focus - Analyst Blog 9:58 a.m. Aug. 12, 2014 - Zacks.com
Intercept Pharma Soars On Liver-Disease Drug Data 9:48 a.m. Aug. 12, 2014 - Investors Business Daily
OvaScience (OVAS) Shows Strength: Stock Up 7% - Tale of the Tape 9:39 a.m. Aug. 12, 2014 - Zacks.com
Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session - Tale of the Tape 8:51 a.m. Aug. 12, 2014 - Zacks.com
Time to Focus on Gilead Sciences (GILD) for Strong Earnings Growth Potential - Tale of the Tape 8:29 a.m. Aug. 12, 2014 - Zacks.com
'Mad Money' Lightning Round: I'm Not Crazy About El Pollo Loco 6:00 a.m. Aug. 12, 2014 - TheStreet.com
Cramer's Lightning Round - El Pollo Loco Is Acting Crazy (8/11/14) 5:44 a.m. Aug. 12, 2014 - Seeking Alpha
What is Your Stock's Earnings Yield? - Screen of the Week 3:17 a.m. Aug. 12, 2014 - Zacks.com
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX
Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma 7:10 a.m. June 26, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt
Gilead Sovaldi sales reach $3.48B, ahead of $2.87B view 4:10 p.m. July 23, 2014 - Russ Britt
Gilead's $6.53B in revs. beats $5.85B estimate 4:10 p.m. July 23, 2014 - Russ Britt
Gilead adj. earns are $2.36/share vs. view of $1.79 4:09 p.m. July 23, 2014 - Russ Britt
Gilead revs. $6.5 billion vs. year-ago $2.77 billion 4:08 p.m. July 23, 2014 - Russ Britt
Gilead Q2 net is $2.20 vs. year-ago 46 cents 4:07 p.m. July 23, 2014 - Russ Britt
4 ways Gilead’s earnings will impact every American 1:30 p.m. July 23, 2014 - Tim Mullaney
Gilead's moment of truth arrives: How does Sovaldi impact earnings? 1:18 p.m. July 23, 2014 - blogs.marketwatch.com
Gilead (GILD) Hits New Lifetime High Today 42 min ago - TheStreet.com
Celladon (CLDN) Falls: Stock Goes Down 6.2% - Tale of the Tape 8:30 a.m. Today - Zacks.com
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day 3:06 a.m. Today - Zacks.com
Apple, Facebook Among 5 Top Rated Big Cap Stocks 7:18 p.m. Aug. 12, 2014 - Investors Business Daily
Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog 5:20 p.m. Aug. 12, 2014 - Zacks.com
Tekmira Shares Continue to Rise in the Search for Ebola Cure - Analyst Blog 4:20 p.m. Aug. 12, 2014 - Zacks.com
Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog 2:49 p.m. Aug. 12, 2014 - Zacks.com
Gilead Sciences Looks Like A Contrarian Short 12:51 p.m. Aug. 12, 2014 - Seeking Alpha
Arrowhead's Hep B Phase 2a Topline Data Imminent - 'Transformational' Potential 12:27 p.m. Aug. 12, 2014 - Seeking Alpha
Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 - Analyst Blog 11:30 a.m. Aug. 12, 2014 - Zacks.com
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog 11:05 a.m. Aug. 12, 2014 - Zacks.com
Supernus (SUPN) Posts Strong Earnings in Q2, Guidance Raised - Analyst Blog 10:38 a.m. Aug. 12, 2014 - Zacks.com
Anacor's Q2 Loss Narrower than Expected, Kerydin in Focus - Analyst Blog 9:58 a.m. Aug. 12, 2014 - Zacks.com
Intercept Pharma Soars On Liver-Disease Drug Data 9:48 a.m. Aug. 12, 2014 - Investors Business Daily
OvaScience (OVAS) Shows Strength: Stock Up 7% - Tale of the Tape 9:39 a.m. Aug. 12, 2014 - Zacks.com
Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session - Tale of the Tape 8:51 a.m. Aug. 12, 2014 - Zacks.com
Time to Focus on Gilead Sciences (GILD) for Strong Earnings Growth Potential - Tale of the Tape 8:29 a.m. Aug. 12, 2014 - Zacks.com
'Mad Money' Lightning Round: I'm Not Crazy About El Pollo Loco 6:00 a.m. Aug. 12, 2014 - TheStreet.com
Cramer's Lightning Round - El Pollo Loco Is Acting Crazy (8/11/14) 5:44 a.m. Aug. 12, 2014 - Seeking Alpha
What is Your Stock's Earnings Yield? - Screen of the Week 3:17 a.m. Aug. 12, 2014 - Zacks.com
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX
Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma 7:10 a.m. June 26, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼
